This vaccine could protect against COVID-19, study shows

Credit: CC0 Public Domain

The measles-mumps-rubella (MMR) vaccine has been theorized to provide protection against COVID-19.

In a new study, researchers found a strong inverse link between mumps titer levels and COVID-19 severity in people under age 42 who have had MMR II vaccinations.

MMR II contains the Edmonston strain of measles, the Jeryl Lynn (B-level) strain of mumps, and the Wistar RA 27/3 strain of rubella.

This adds to other associations demonstrating that the MMR vaccine may be protective against COVID-19.

It also may explain why children have a much lower COVID-19 case rate than adults, as well as a much lower death rate.

The majority of children get their first MMR vaccination around 12 to 15 months of age and a second one from 4 to 6 years of age.

The research was reported by the American Society for Microbiology.

In the study, the researchers divided 80 people into 2 groups. The MMR II group consisted of 50 U.S. born people who would primarily have MMR antibodies from the MMR II vaccine.

A comparison group of 30 people had no record of MMR II vaccinations, and would primarily have MMR antibodies from other sources, including prior measles, mumps, and/or rubella illnesses.

The researchers found a strong inverse link between mumps titers and COVID-19 severity within the MMR II group.

This is the first immunological study to test the link between the MMR II vaccine and COVID-19.

The strong inverse correlation between mumps titers and COVID-19 indicates that there is a relationship involved that warrants further research.

The MMR II vaccine is considered a safe vaccine with very few side effects.

If it has the ultimate benefit of preventing infection from COVID-19, preventing the spread of COVID-19, reducing the severity of it, or a combination of any or all of those, it is a very high reward low-risk ratio intervention.

Maximum seropositivity is achieved through two vaccinations at least 28 days apart.

Based on this study, it would be prudent to vaccinate those over 40 regardless of whether or not they already have high serum MMR titers.

One author of the study is Jeffrey E. Gold, president of the World Organization, in Watkinsville, Georgia.

The study is published in mBio.

Copyright © 2020 Knowridge Science Report. All rights reserved.